Scientists at USC Michelson Center for Convergent Bioscience and Japan’s Nagoya University find and test a promising drug that stops cancer by interfering with the cancer cells’ metabolism and other circadian-related functions
A new drug shows potential to halt cancer cells’ growth by stunting the cells’ biological clock.
The findings from scientists at the USC Michelson Center for Convergent Bioscience and Nagoya University’s Institute of Transformative BioMolecules (ITbM) advance a burgeoning area of research: turning the body’s circadian rhythms against cancer.
Their study, conducted on human kidney cancer cells and on acute myeloid leukemia in mice, was published Jan. 23 in the journal Science Advances.
Scientists know that disrupting sleep and other elements of humans’ circadian rhythm can harm health. The same is true for the circadian clock of cells themselves. If researchers could disturb the circadian clock of cancer cells, they theorize, they could potentially hurt or kill those cells.
The scientists found that a molecule named GO289 targets an enzyme that controls the cell’s circadian rhythm. This drug-protein interaction then disrupts the functions of four other proteins that are important for cell growth and survival.
Human bone cancer cells stopped growing when a drug molecule jammed their circadian rhythm during a study that appears in Science Advances. Photo courtesy of the Kay lab at the USC Michelson Center for Convergent Bioscience.
In effect, GO289 can jam the cogs of the cell’s circadian clock, slowing its cycles. And it can do so with little impact to healthy cells.
“In some cancers, the disease takes over the circadian clock mechanism and uses it for the evil purpose of helping itself grow,” said Steve Kay, director of convergent biosciences at the USC Michelson Center and USC Provost Professor of Neurology, Biomedical Engineering and Biological Sciences. “With GO289, we can interfere with those processes and stop the cancer from growing.”
Kay is among several scientists from USC Dornsife College of Letters, Arts and Sciences, USC Viterbi School of Engineering and Keck School of Medicine of USC who are collaborating across multiple disciplines to find new solutions for treating cancer, neurological disease and cardiovascular disease.
Finding the right candidate
On its initial interactions with human bone cancer cells, GO289 appeared to slow the tumors’ circadian clock as it targeted an enzyme, named CK2.
To see if GO289 consistently hindered other cancers in the same way, the scientists then tested it on human kidney cancer cells and on mice with acute myeloid leukemia. They found that GO289 specifically affected cancer cell metabolism and other circadian-related functions that normally would enable the cancer to grow and spread.
Kay is optimistic about the findings. “This could become an effective new weapon that kills cancer,” he said.
Learn more: Cancer has a biological clock and this drug may keep it from ticking
The Latest on: Cancer
[google_news title=”” keyword=”cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer
- Breast cancer: Woman's reconstruction delayed three timeson June 1, 2023 at 2:59 pm
A breast cancer survivor has said she feels "cast aside" due to reconstructive surgery being postponed three times this year. Karen Rogers, 57, from Magor, Monmouthshire, was given a mastectomy six ...
- KKR-Backed Cancer-Treatment Provider GenesisCare Files for Bankruptcyon June 1, 2023 at 12:50 pm
The Australia-based company plans to seek a buyer for its U.S. business, which includes 130 radiation-therapy centers.
- Florida Cancer Specialists & Research Institute Cutting-Edge Clinical Research Presented at 2023 ASCO® Annual Meetingon June 1, 2023 at 12:40 pm
Florida's Largest Community Oncology Practice Contributes Study Results in 23 Abstracts, Presentations and PublicationsFCS Abstracts at 2023 ...
- AstraZeneca drug combo gets US nod to treat a type of prostate canceron June 1, 2023 at 12:17 pm
AstraZeneca said on Thursday that a combination of its cancer drug Lynparza and abiraterone has been approved in the United States for the treatment of BRCA-mutated metastatic castration-resistant ...
- FDA considers temporary cancer drug imports from unapproved companies to ease U.S. shortageon June 1, 2023 at 11:43 am
Shortages of cisplatin and carboplatin, bedrock cancer treatments, have forced some hospitals to ration the drugs.
- Local businesses raise funds for dad with rare canceron June 1, 2023 at 10:47 am
Local firms in Northampton have been helping to raise funds for a business owner who was diagnosed with cancer. Justin Vanezi, 39, is a father, the owner of a local Greek food business and a DJ. He ...
- Doctors are pressing adults to have more lung cancer screeningson June 1, 2023 at 10:36 am
Low-dose CT screenings can detect cancer earlier and treat patients faster. What is a low-dose CT screening? What are the first signs of lung cancer?
- Investing in quality cancer careon June 1, 2023 at 9:53 am
Pallavi P. Kumar, M.D., became the director of medical oncology for LifeBridge Health's Alvin & Lois Lapidus Cancer Institute in summer 2021.
- Are you truly at risk for prostate cancer? Adding genetics may give more accurate PSA testson June 1, 2023 at 9:03 am
Others have low PSA that might lead to aggressive tumors being missed in screenings. This has led to overtreatment of men who didn't need biopsies or whose cancers would never have become dangerous ...
- AI technology catches cancer before symptoms with Ezra, a full-body MRI scanneron June 1, 2023 at 6:56 am
Combining MRI imaging technology with artificial intelligence, Ezra scans for possible cancer in up to 13 organs and also monitors for hundreds of other conditions.
via Bing News